Axsome Therapeutics 3Q 2026: Revenue $259.7M, Net loss $12.9M, EPS $(0.25) — 10-Q Summary
Axsome Therapeutics reported Q3 2026 revenue of $259.7M, up 51.9% YoY, with a net loss of $12.9M, narrower than the prior-year quarter. EPS was $(0.25). Sales of AUVELITY, SUNOSI, and SYMBRAVO increased, and the FDA accepted the AXS-12 NDA with a 2027 target date.
How this was made
The 30-second read
Why it matters
Fresh quarterly numbers (revenue growth and loss narrowing) combined with FDA acceptance of the AXS-12 narcolepsy NDA and Phase 3 trial progress can shift expectations for commercialization and regulatory timelines.
Market read
Traders can reassess near-term risk and sentiment based on improved quarterly losses, accelerating revenue, and a concrete FDA timeline for AXS-12.
What to watch
The summary does not quantify guidance, cash runway, or detailed trial outcomes; traders may need to verify balance-sheet liquidity and any risk factors in the full 10-Q before extrapolating profitability improvement.
Background
The piece is a 10-Q summary for Axsome Therapeutics’ third quarter of 2026, including financial results and several business/regulatory updates.
Ticker impact
Axsome Therapeutics reported 3Q 2026 revenue of $259.7M (+51.9% YoY) and narrowed net loss to $12.9M, with EPS of $(0.25).
Likely upward bias as investors price in improving profitability trajectory and de-risking from FDA NDA acceptance and trial advancement.
The article provides fresh quarterly financials and specific regulatory/trial milestones (FDA accepted AXS-12 NDA with a May 1, 2027 target date), which can re-rate near-term risk and sentiment.
Market effects
Biotech investors may view the FDA acceptance and improving losses as supportive for the broader commercial-stage CNS/neurology drug cohort.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond healthcare/biopharma flows.
Modest, as the catalysts are company-specific (FDA NDA acceptance and trial updates) rather than a global regulatory shift.
Counterpoint
Revenue growth may be driven by product ramp timing, while R&D cost increases are expected, which could pressure future margins despite the narrower net loss this quarter.
Key entities
- companyAxsome Therapeutics
US-listed biotech reporting 3Q 2026 financial results and updates on AUVELITY, SUNOSI, SYMBRAVO, and the AXS-12 NDA.
- regulatorFDA
Accepted the AXS-12 narcolepsy NDA and set a May 1, 2027 target date.
- productAUVELITY
Reported higher US sales in the quarter and launched an agitation associated with dementia due to Alzheimer’s indication in June 2026.
- productSUNOSI
Reported increased sales to $38.5M in the quarter.
- productSYMBRAVO
Reported sales of $3.9M as its US launch gained traction.
